ARTA
CYTO

A.R.T. Advisors’s Altamira Therapeutics Ltd CYTO Stock Holding History

A.R.T. Advisors’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2
Closed -$15K – 1796
2018
Q2 		$15K Buy
+2
New +$21.1K ﹤0.01% 1367
2017
Q4 		– Hold
0
– -$16K – 1745
2017
Q3 		– Hold
0
– – – 1292
2017
Q2 		– Hold
0
– – – 1358
2017
Q1 		– Hold
0
– – – 1385

Other funds holding CYTO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

A.R.T. Advisors's CYTO Position: Q3 2018 in Review

A.R.T. Advisors sold out of Altamira Therapeutics Ltd (CYTO) in Q3 2018, closing a stake of 2 shares — an estimated $15K sold.

A.R.T. Advisors first reported a position in CYTO in Q2 2018 and held it in 1 quarter. The position peaked at $15K in Q2 2018. 7 funds tracked by Wall St. Rank hold CYTO as of Q3 2018.

  • A.R.T. Advisors reported no remaining Altamira Therapeutics Ltd position as of Q3 2018 after selling out during the quarter.
  • A.R.T. Advisors sold 2 Altamira Therapeutics Ltd shares in Q3 2018, an estimated $15K.
  • A.R.T. Advisors first reported a position in Altamira Therapeutics Ltd in Q2 2018 and held it in 1 quarter.
  • A.R.T. Advisors's Altamira Therapeutics Ltd position peaked at $15K in Q2 2018.
  • 7 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2018.

Based on A.R.T. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.